- Home
- IONS vs RRX Comparison
IONS vs RRX Comparison
Compare IONS & RRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IONS | RRX |
|---|---|---|
| Founded | 1989 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 14.0B |
| IPO Year | 1996 | 1994 |
Fundamental Metrics
Financial Performance| Metric | IONS | RRX |
|---|---|---|
| Price | $77.82 | $204.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 10 |
| Target Price | $93.36 | ★ $210.70 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.69% |
| EPS Growth | 21.71 | ★ 42.86 |
| EPS | N/A | ★ 0.96 |
| Revenue | N/A | ★ $3,257,100,000.00 |
| Revenue This Year | N/A | $4.20 |
| Revenue Next Year | $77.99 | $12.13 |
| P/E Ratio | ★ N/A | $217.54 |
| Revenue Growth | N/A | ★ 5.21 |
| 52 Week Low | $32.00 | $127.96 |
| 52 Week High | $86.74 | $236.35 |
Technical Indicators
Market Signals| Indicator | IONS | RRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.30 | 48.29 |
| Support Level | $75.66 | $197.98 |
| Resistance Level | $82.85 | $222.63 |
| Average True Range (ATR) | 2.45 | 9.14 |
| MACD | 0.28 | -1.30 |
| Stochastic Oscillator | 97.08 | 12.83 |
Price Performance
Historical ComparisonAbout IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
About RRX Regal Rexnord Corporation
Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The three operating segments include Automation & Motion Control (AMC) segment; Industrial Powertrain Solutions (IPS) segment, which derives maximum revenue; and Power Efficiency Solutions (PES) segment. Geographically, the company operates in North America, Europe, Asia, and Rest of the world, of which it derives maximum revenue from North America.